AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20701016 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD screening
Number of subjects: 0
Study 19146124 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate 3600 Deep Clean (AFT version)
Number of subjects: 109
Study 19146124 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate 3600 Deep Clean (stapled version)
Number of subjects: 109
Study 19146124 — intervention group
Group type: COMPARATOR
Intervention: Oral B Indicator
Number of subjects: 109
Study 15990003 — intervention group
Group type: EXPERIMENTAL
Intervention: LCAF (Late course accelerated hyperfractionated radiotherapy)
Number of subjects: 111
Study 15990003 — intervention group
Group type: COMPARATOR
Intervention: LCAF+CT (Late course accelerated hyperfractionated radiotherapy plus concurrent chemotherapy)
Number of subjects: 111
Study 19753739 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day itraconazole for 3 days
Number of subjects: 60
Study 19753739 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg/day itraconazole for 1 day
Number of subjects: 60
Study 19753739 — intervention group
Group type: COMPARATOR
Intervention: 200 mg/day itraconazole for 5 days
Number of subjects: 60
Study 10726429 — intervention group
Group type: EXPERIMENTAL
Intervention: Short rest interval (40 sec)
Number of subjects: 14
Study 10726429 — intervention group
Group type: COMPARATOR
Intervention: Long rest interval (160 sec)
Number of subjects: 14
Study 10726429 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 14
Study 8749210 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressed wounds
Number of subjects: 68
Study 8749210 — intervention group
Group type: COMPARATOR
Intervention: Exposed wounds
Number of subjects: 68
Study 2028586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, 4 mg
Number of subjects: 18
Study 2028586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide, 250 mg
Number of subjects: 18
Study 2028586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7032341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization treatment
Number of subjects: 33
Study 7032341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31280790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (CBGT) + 4 resilience and coping strategy sessions (total 16 sessions)
Number of subjects: 100
Study 31280790 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral group therapy (CBGT)
Number of subjects: 100
Study 29441577 — intervention group
Group type: EXPERIMENTAL
Intervention: CHARM intervention
Number of subjects: 1081
Study 29441577 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1081
Study 27492601 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal insulin (40 IU)
Number of subjects: 16
Study 27492601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 25005880 — intervention group
Group type: EXPERIMENTAL
Intervention: Target temperature of 33 °C
Number of subjects: 950
Study 25005880 — intervention group
Group type: COMPARATOR
Intervention: Target temperature of 36 °C
Number of subjects: 950
Study 22172922 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led cardiac rehabilitation
Number of subjects: 110
Study 22172922 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 110
Study 20335572 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus nadroparin (2850 IU)
Number of subjects: 364
Study 20335572 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone (80 mg)
Number of subjects: 364
Study 20335572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 17404460 — intervention group
Group type: EXPERIMENTAL
Intervention: JO plans with four apertures per beam angle (JO-4A)
Number of subjects: 10
Study 17404460 — intervention group
Group type: COMPARATOR
Intervention: 3D plans
Number of subjects: 10
Study 17404460 — intervention group
Group type: COMPARATOR
Intervention: MLC plans
Number of subjects: 10
Study 17404460 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverse IMRT plans
Number of subjects: 10
Study 17404460 — intervention group
Group type: EXPERIMENTAL
Intervention: JO plans with varying apertures (2 to 7)
Number of subjects: 10
Study 16050419 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT measurement before GAT
Number of subjects: 60
Study 16050419 — intervention group
Group type: EXPERIMENTAL
Intervention: CCT measurement after GAT
Number of subjects: 60
Study 16050419 — intervention group
Group type: EXPERIMENTAL
Intervention: GAT measurement before pachymetry
Number of subjects: 60
Study 16050419 — intervention group
Group type: EXPERIMENTAL
Intervention: GAT measurement after pachymetry
Number of subjects: 60
Study 12131743 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation in spinal cord injury patients
Number of subjects: 20
Study 12131743 — intervention group
Group type: COMPARATOR
Intervention: Transcranial magnetic stimulation in control participants
Number of subjects: 20
Study 9990745 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% CO2-enriched air (UCS)
Number of subjects: 96
Study 9990745 — intervention group
Group type: COMPARATOR
Intervention: 13% CO2-enriched air (UCS)
Number of subjects: 96
Study 9990745 — intervention group
Group type: EXPERIMENTAL
Intervention: High anxiety sensitivity
Number of subjects: 96
Study 9990745 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium anxiety sensitivity
Number of subjects: 96
Study 9990745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low anxiety sensitivity
Number of subjects: 96
Study 7774735 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) gel (2 mg for primigravidae, 1 mg for parous)
Number of subjects: 260
Study 7774735 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) gel
Number of subjects: 260
Study 7774735 — intervention group
Group type: COMPARATOR
Intervention: Forewater amniotomy
Number of subjects: 260
Study 2274632 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg to 80 mg depending on response and side effects)
Number of subjects: 39
Study 7195329 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive caregiving environment
Number of subjects: 0
Study 7195329 — intervention group
Group type: COMPARATOR
Intervention: Nonsupportive caregiving environment
Number of subjects: 0
Study 29898788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixatimod (PG545) administered by intravenous (IV) infusion at a dose of up to 100 mg.
Number of subjects: 0
Study 29898788 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixatimod in combination with PD-1 inhibitors (e.g., nivolumab).
Number of subjects: 0
Study 27840257 — intervention group
Group type: EXPERIMENTAL
Intervention: eBV 0.2mL
Number of subjects: 20
Study 27840257 — intervention group
Group type: COMPARATOR
Intervention: BV 0.2mL
Number of subjects: 20
Study 23598957 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) for 2 months
Number of subjects: 77
Study 23598957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CPAP)
Number of subjects: 77
Study 23715142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower eyelid blepharoplasty with periorbital fat mobilization and arcus marginalis redrape, routine lateral canthal support
Number of subjects: 50
Study 23715142 — intervention group
Group type: COMPARATOR
Intervention: Conservatively standard fat‐resection lower eyelid blepharoplasty, routine lateral canthal support
Number of subjects: 50
Study 20863432 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia using isoflurane
Number of subjects: 60
Study 20863432 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anesthesia using ropivacaine
Number of subjects: 60
Study 20863432 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 19085781 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser refractive surgery (OP group)
Number of subjects: 189
Study 15883431 — intervention group
Group type: EXPERIMENTAL
Intervention: S-equol
Number of subjects: 3
Study 15883431 — intervention group
Group type: EXPERIMENTAL
Intervention: R-equol
Number of subjects: 3
Study 12556406 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 12
Study 12556406 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 12
Study 12556406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10721926 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-folic acid (IFA) supplements
Number of subjects: 90
Study 10721926 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what the control was)
Number of subjects: 90
Study 9174874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 mg
Number of subjects: 172
Study 9174874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 16 mg
Number of subjects: 172
Study 9174874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 14621818 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 0
Study 14621818 — intervention group
Group type: COMPARATOR
Intervention: St. Thomas Hospital (ST) solution
Number of subjects: 0
Study 4083859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin with a lactobacillus preparation
Number of subjects: 12
Study 4083859 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin alone
Number of subjects: 12
Study 4083859 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin followed 1 h later by the lactobacillus preparation
Number of subjects: 12
Study 31592811 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal ileocolic anastomosis (IIA)
Number of subjects: 140
Study 31592811 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal ileocolic anastomosis (EIA)
Number of subjects: 140
Study 29915975 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA1 therapy
Number of subjects: 68
Study 29915975 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB therapy
Number of subjects: 68
Study 27596486 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic assessment with the EMBalance decision support system (DSS)
Number of subjects: 200
Study 27596486 — intervention group
Group type: COMPARATOR
Intervention: Standard practice (diagnostic assessment without the DSS)
Number of subjects: 200
Study 25422027 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate (40-45% of energy), increased-protein (25-30%) diet
Number of subjects: 111
Study 25422027 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate (55-60%), moderate-protein (15%) diet
Number of subjects: 111
Study 22409295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 500 mg
Number of subjects: 59
Study 22409295 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab 1000 mg
Number of subjects: 59
Study 22409295 — intervention group
Group type: EXPERIMENTAL
Intervention: O-CHOP (combined with ofatumumab)
Number of subjects: 59
Study 22409295 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 59
Study 20813813 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at both general acupuncture points and ah shi points
Number of subjects: 36
Study 20813813 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture at general acupuncture points only
Number of subjects: 36
Study 18437442 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 30 mg daily for 6 months
Number of subjects: 50
Study 18437442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 18437442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 50
Study 18437442 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary glyceroltrinitrate
Number of subjects: 50
Study 18437442 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 50
Study 15824254 — intervention group
Group type: COMPARATOR
Intervention: Choline‐containing compounds, phosphocreatine, myo‐inositol, total N‐acetyl‐aspartate (tNAA), and glutamate‐glutamine concentrations in cortical gray matter (CGM)
Number of subjects: 43
Study 15824254 — intervention group
Group type: COMPARATOR
Intervention: Myo‐inositol and total N‐acetyl‐aspartate (tNAA) concentrations in normal-appearing white matter (NAWM)
Number of subjects: 43
Study 15824254 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded Disability Status Scale score
Number of subjects: 43
Study 15824254 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton density lesion load
Number of subjects: 43
Study 12869969 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sputter-coated titanium specimens fired in reduced argon atmosphere
Number of subjects: 80
Study 12869969 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold sputter-coated titanium specimens fired in vacuum
Number of subjects: 80
Study 12869969 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional Au‐Pd‐In metal‐ceramic alloy)
Number of subjects: 80
Study 12869969 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon group without gold coating
Number of subjects: 80
Study 12869969 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon group with gold coating
Number of subjects: 80
Study 12869969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum group without gold coating
Number of subjects: 80
Study 12869969 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum group with gold coating
Number of subjects: 80
Study 10507579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention aimed at clinic leadership
Number of subjects: 0
Study 10507579 — intervention group
Group type: COMPARATOR
Intervention: Intervention aimed at all clinic physicians
Number of subjects: 0
Study 8917033 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracheal pressure triggering
Number of subjects: 14
Study 8917033 — intervention group
Group type: COMPARATOR
Intervention: Flow‐by triggering
Number of subjects: 14
Study 8917033 — intervention group
Group type: COMPARATOR
Intervention: Conventional pressure triggering
Number of subjects: 14
Study 1847240 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction combination chemotherapy (ICC)
Number of subjects: 48
Study 1847240 — intervention group
Group type: COMPARATOR
Intervention: Thoracic irradiation (after ICC)
Number of subjects: 48
Study 6489410 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline 4 mg/kg
Number of subjects: 20
Study 6489410 — intervention group
Group type: COMPARATOR
Intervention: Theophylline 8 mg/kg
Number of subjects: 20
Study 31316682 — intervention group
Group type: EXPERIMENTAL
Intervention: LIPUS combined with TENS therapy
Number of subjects: 40
Study 31316682 — intervention group
Group type: COMPARATOR
Intervention: Only TENS therapy
Number of subjects: 40
Study 29566002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivor vignette
Number of subjects: 593
Study 29566002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer survivor during active follow-up
Number of subjects: 593
Study 29566002 — intervention group
Group type: EXPERIMENTAL
Intervention: Widowed respondents
Number of subjects: 593
Study 29566002 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of disclosure preference
Number of subjects: 593
Study 27355508 — intervention group
Group type: EXPERIMENTAL
Intervention: ART delivery strategies during the postpartum period
Number of subjects: 0
Study 27355508 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence club model for long-term adherence and retention
Number of subjects: 0
Study 27355508 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of models of care
Number of subjects: 0
Study 24499010 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-evoked potentials (AEP) monitoring
Number of subjects: 37
Study 24499010 — intervention group
Group type: COMPARATOR
Intervention: Ramsay sedation scale (RSS) monitoring
Number of subjects: 37
Study 22540372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatogastrostomy
Number of subjects: 360
Study 22540372 — intervention group
Group type: COMPARATOR
Intervention: Pancreatojejunostomy
Number of subjects: 360
Study 20795962 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior fundoplication
Number of subjects: 103
Study 20795962 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic posterior fundoplication
Number of subjects: 103
Study 22642657 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.05-0.22 U/kg)
Number of subjects: 20
Study 15971720 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral modification and antimuscarinics
Number of subjects: 0
Study 15971720 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromodulation, denervation techniques, and bladder augmentation
Number of subjects: 0
Study 12888148 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4607
Study 12888148 — intervention group
Group type: COMPARATOR
Intervention: Sibrafiban
Number of subjects: 4607
Study 10583435 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 group (micronised oestradiol 2 mg)
Number of subjects: 60
Study 10583435 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 + P group (E2 + trimegestone 0.5 mg)
Number of subjects: 60
Study 10583435 — intervention group
Group type: COMPARATOR
Intervention: E2 + D group (E2 + dydrogesterone 10 mg)
Number of subjects: 60
Study 10583435 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 60
Study 8904612 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 250 mg weekly for 4 weeks
Number of subjects: 106
Study 8904612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 1678925 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin alone (1 to 80 mg/day)
Number of subjects: 1180
Study 1678925 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40 to 120 mg twice daily)
Number of subjects: 1180
Study 1678925 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin (5 mg) plus methyclothiazide (2.5 to 5 mg)
Number of subjects: 1180
Study 1678925 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin alone
Number of subjects: 1180
Study 1678925 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin plus methyclothiazide (2.5 mg)
Number of subjects: 1180
Study 1678925 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin plus methyclothiazide (5 mg)
Number of subjects: 1180
Study 7160179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimule cap
Number of subjects: 32
Study 7160179 — intervention group
Group type: COMPARATOR
Intervention: Cavity Rim Cap (CRC)
Number of subjects: 32
Study 7160179 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimule cap (long-term users)
Number of subjects: 32
Study 29671901 — intervention group
Group type: EXPERIMENTAL
Intervention: Doll Therapy (DT)
Number of subjects: 29
Study 29671901 — intervention group
Group type: COMPARATOR
Intervention: Hand warmers (active control)
Number of subjects: 29
Study 28395936 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg
Number of subjects: 551
Study 28395936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study 25519721 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 0
Study 25519721 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian tools
Number of subjects: 0
Study 23748507 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 737
Study 23748507 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin (sita)
Number of subjects: 737
Study 23748507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EQW and sita
Number of subjects: 737
Study 20884959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 40 mg/day
Number of subjects: 233
Study 20884959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg/day
Number of subjects: 233
Study 20884959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 18416265 — intervention group
Group type: EXPERIMENTAL
Intervention: Acri. Smart IOL
Number of subjects: 45
Study 18416265 — intervention group
Group type: EXPERIMENTAL
Intervention: AT-45 IOL
Number of subjects: 45
Study 18416265 — intervention group
Group type: EXPERIMENTAL
Intervention: presbyLASIK
Number of subjects: 45
Study 18416265 — intervention group
Group type: COMPARATOR
Intervention: Control (monofocal IOL)
Number of subjects: 45
Study 16847590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mantram intervention (n = 46)
Number of subjects: 93
Study 16847590 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (n = 47)
Number of subjects: 93
Study 16847590 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual mantram practice
Number of subjects: 93
Study 12838524 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 162
Study 12838524 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 162
Study 10811503 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-hour infusion of doxorubicin (arm A)
Number of subjects: 120
Study 10811503 — intervention group
Group type: COMPARATOR
Intervention: Intravenous injection of doxorubicin (arm B)
Number of subjects: 120
Study 8891089 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 115
Study 8891089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 1797602 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg simethicone
Number of subjects: 10
Study 1797602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 7049301 — intervention group
Group type: EXPERIMENTAL
Intervention: Emepronium bromide (Cetiprin)
Number of subjects: 0
Study 7049301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31111801 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day AL initiation regimen (ALNCD + 30 mg oral aripiprazole for 1 day)
Number of subjects: 0
Study 31111801 — intervention group
Group type: COMPARATOR
Intervention: 21-day AL initiation regimen (AL + 15 mg/day of oral aripiprazole for 21 days)
Number of subjects: 0
Study 29849032 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (ET) for 12 months, mean 140 mins per week at 75% Hrmax
Number of subjects: 50